{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LIN+Dose+C", "query": { "intervention": "LIN Dose C" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 121, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LIN+Dose+C&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T02:56:52.792Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00267748", "title": "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Sunitinib Malate Continuous Daily Dosing", "type": "DRUG" }, { "name": "Sunitinib Malate Schedule 4/2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2005-12", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-09-05", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 156, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 114 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267748" }, { "nct_id": "NCT06137118", "title": "AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia (B-ALL)" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 255, "start_date": "2023-12-29", "completion_date": "2028-09-15", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06137118" }, { "nct_id": "NCT02386826", "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Colorectal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "INC280", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-09-22", "completion_date": "2023-08-23", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 5, "location_summary": "Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02386826" }, { "nct_id": "NCT04476329", "title": "Optimization for Regorafenib in HCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Regorafenib 40 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SC Liver Research Consortium, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-01-21", "completion_date": "2021-12-10", "has_results": false, "last_update_posted_date": "2021-12-30", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04476329" }, { "nct_id": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GAd-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "GAd-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "GAd20-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nouscom SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-10-21", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041310" }, { "nct_id": "NCT00325507", "title": "Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "TroVax", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oxford BioMedica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-11", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325507" }, { "nct_id": "NCT01095120", "title": "Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Stomach", "Adenocarcinoma of Esophagogastric Junction" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-03", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 3, "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095120" }, { "nct_id": "NCT01765582", "title": "Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 280, "start_date": "2013-01-23", "completion_date": "2016-03-14", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 45, "location_summary": "Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01765582" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT05186974", "title": "Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy (SG)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2022-05-30", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-06T02:56:52.792Z", "location_count": 22, "location_summary": "Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05186974" } ] }